A single protein may be holding back CAR T cancer therapy

A newly identified protein may be one of the biggest obstacles holding CAR T-cell therapy back.

Researchers found that NFIL3 causes these engineered immune cells to become exhausted and lose their cancer-fighting power over time.

When NFIL3 was disabled, the cells remained stronger for longer and controlled tumors more effectively in animal models. ...